Everlywell Launches AI Breast Cancer Tool for Patients — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Everlywell launched an AI-based breast cancer risk prediction algorithm directly to consumers last week, marketed on its site with the call to action "Don't wait. Choose to be informed."
- The product is described as one of a new generation of AI-based risk prediction algorithms applied to medical images.
- Everlywell has spent the past decade selling at-home lab tests — blood glucose, celiac screening, and more — directly to consumers, making the breast cancer tool a leap from consumer wellness into clinical-grade AI imaging.
- The launch is covered in Part 5 of STAT's "Paying for AI" series, which examines how clinical AI tools influence healthcare affordability and patients' long-term health.
Why it matters: Everlywell's decade-long direct-to-consumer testing business is now stretching into AI medical imaging, putting a clinical-grade risk prediction tool in front of patients without a physician intermediary. The launch lands inside STAT's series on how clinical AI tools affect healthcare costs and patient outcomes, framing it as a live test of whether consumers will pay out-of-pocket for AI-powered assessments outside traditional clinical channels.
Ask SkimNews
